Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | TTM | |||
| ROCE % ⓘ | 231.6% | -14.4% | -3.7% | -7.7% | -274.5% | 108.8% | -65.6% | 18.1% | -49.1% | 131.8% | - | ||
| Value Creation Index ⓘ | NA | -2.0 | -1.3 | -1.6 | -20.6 | 6.8 | -5.7 | 0.3 | -4.5 | 8.4 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | ||
| YoY Gr. Rt. % | - | NA | 33.3% | 25% | 100% | -10% | -44.4% | 60% | 0% | 62.5% | - | ||
| Adj EPS ⓘ | -0.1 | 0 | 0 | 0 | 0.1 | 0 | -0 | 0 | -0 | 0 | 0 | ||
| YoY Gr. Rt. % | - | NA | -100% | NA | NA | -66.7% | -150% | NA | NA | NA | - | ||
| BVPS (₹) ⓘ | -0.1 | -0.1 | -0.1 | -0.1 | 0 | 0 | 0 | 0 | 0 | 0.1 | 1.1 | ||
| Adj Net Profit ⓘ | -0.1 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0.1 | 0 | ||
| Cash Flow from Ops. ⓘ | -0.2 | 0 | 0 | 0 | -0.1 | 0 | 0 | 0 | 0 | 0 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | NA | 5.4% | 37.5% | 62.5% | ||||||||
| Adj EPS ⓘ | NA | -7.8% | NA | NA | ||||||||
| BVPS ⓘ | 0 | 43.1 | 44.2 | 500 | ||||||||
| Share Price | 22.4% | 27.3% | 173.3% | 414.9% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | TTM | ||
| Return on Equity % ⓘ | 232.3 | -14.4 | -3.6 | -7.6 | -274.3 | 108.6 | -65.8 | 17.8 | -49.5 | 131.7 | 0 | |
| Op. Profit Mgn % ⓘ | 0 | -25.3 | -27.1 | 6.9 | 32.4 | 30.9 | -41 | 2.9 | -11.6 | 41.3 | 0 | |
| Net Profit Mgn % ⓘ | 0 | 39.5 | 7.8 | 11.6 | 85.6 | 30.8 | -38.8 | 4.9 | -11.4 | 41.3 | 0 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Working Cap Days ⓘ | 0 | 25 | 53 | 45 | 28 | 60 | 109 | 59 | 76 | 61 | 0 | |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Sales growth is growing at healthy rate in last 3 years 37.51%
Return on Equity has declined versus last 3 years average to 0.00%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0 | -1.3 |
| TTM Sales (₹ Cr.) | 0 | 0.4 |
| BVPS (₹.) ⓘ | 1.1 | 0 |
| Reserves (₹ Cr.) ⓘ | -12 | -13 |
| P/BV ⓘ | 10.84 | 0.00 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1.87 / 12.08 |
| All Time Low / High (₹) | 0.36 / 40.00 |
| Market Cap (₹ Cr.) | 15.4 |
| Equity (₹ Cr.) | 13.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 82.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Welcure Drugs & Pharmaceuticals Ltd. (WDPL) was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.
Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation.
Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base.
In March 2000 WDPL entered into a five-year agreement with Bihar Drugs and Chemicals Ltd (BDCL), a subsidiary of Bihar State Pharmaceutical and Chemical Development Corporation Ltd, for manufacturing various pharmaceutical pro ducts (both generic as well as branded) for the latter on loan licence basis. WDPL manufactures the drugs in tablet, capsule and syrup form at its facilities situated in Bhiwadi (Rajasthan).
The Company’s principal activity is to manufacture pharmaceutical products. The products of the Company include tablets, capsules, liquid orals and dry syrups.
Product range of the company includes:
Welcure manufactures a large variety of pharmaceutical formulations, covering almost all ailments, about 250 in numbers. Some of our known products include:
My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
